A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

NCT05244070 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

5

Enrollment

INDUSTRY

Sponsor class

Stopped Business objectives have changed.

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma

Interventions

DRUG: BMS-986403
DRUG: Fludarabine
DRUG: Cyclophosphamide

Sponsor

Bristol-Myers Squibb